New ECF-Sponsored Ophthalmic Pathology Fellowship at Emory Eye Center with Hans Grossniklaus, MD, MBA

dr_grossniklaus
Hans Grossniklaus, MD, MBA, founding director of the Ocular Oncology and Pathology Services at Emory Eye Center in Atlanta, Georgia

We are fortunate to have partnered with Hans Grossniklaus, MD, MBA who is founding director of the Ocular Oncology and Pathology Services at Emory Eye Center. Through this partnership, The Eye Cancer Foundation (ECF) is continuing its work supporting fellowship education for doctors from unserved countries.

Dr. Hans E. Grossniklaus will host one ECF fellow per year from an unserved country or area. The fellowship will focus on ophthalmic pathology, and doctors completing the program will return to practice in their home country. These new eye pathologists will be trained to provide crucial eye pathology services for our emerging retinoblastoma fellows.

Ophthalmic pathology is the subspecialty of surgical pathology and ophthalmology that primarily deals with the diagnosis and characterization of cancer and non-cancerous diseases of the eye, eyelids and orbit. Ophthalmic pathologists are vital in providing practicing ophthalmologists with information about causes, pathogenesis, and the prognosis of ocular diseases.

The new ECF fellowship will provide a $30,000 grant for one year of travel and expenses. Candidates must have completed a residency in ophthalmology. For consideration, they will need to submit a letter of recommendation from their local chairman or hospital director. Included in this letter must be a clear statement that the prospective fellow will be supported to perform ophthalmic pathology upon return to their home country. Failure to return home would make the fellow liable to repay the grant money.

The Emory Eye Center is the largest, most comprehensive clinical eye care facility in the southeast United States. Dr. Grossniklaus is widely recognized as a national leader in eye disease treatment and education, as well as a pioneer in eye disease research. Learn more here.

This ECF-sponsored ophthalmic oncology fellowship provides doctors training they would be unable to get in their home country. Their presence will reduce mortality and save vision in countries that currently lack the resources to effectively diagnose and treat many eye diseases, including eye cancer.

If you are a candidate in an unserved country interested in the fellowship, or would like to recommend a candidate, please contact The Eye Cancer Foundation at (212) 832-8170 or click here to email us.


ECF Fellow Publishes Uveal Melanoma Study in Middle East

Dr. Ahmad Shokri Zewar from Yemen was the first author of a recent study to evaluate the features and outcomes relating to the management of uveal melanoma in King Hussein Cancer Center in Jordan. Zewar conducted the study with Dr. Yacoub A.Yousef, a collaboration that was possible thanks to The Eye Cancer Foundation’s Fellowship program that supports training of eye cancer specialists from unserved countries.

Dr. Ahmad Shokri Zewar & Dr. Yacoub A.Yousef

While the paper focused specifically on King Hussein Cancer Center, the aim was to complete a study that could be generalized to other referral tertiary cancer centers in the Middle East.

The study focused on 46 patients with uveal melanoma between 2006 and 2014. There were actually 76 patients diagnosed in the hospital over that time period, but 30 were excluded from the study due to lack of data or because they didn’t receive follow-up. This is a relatively low number, and researchers concluded it provides the impression that uveal melanoma occurs with a low frequency in the Middle East as compared to Western countries.

Eighteen eyes (39% of the patients) were treated by primary enucleation, and 28 eyes (61%) were treated by I-125 radioactive plaque therapy. Two of the eyes treated by plaque therapy were subsequently enucleated. Many of the patients were not diagnosed until the disease had significantly advanced.

The authors write:

“In our review, a significant percentage (65%) of affected eyes had a visual acuity of less than 0.1, which is worse than the visual acuity for of patients studied in the COMS study where only 33% had visual acuity of less than 0.1 (9). This finding might be explained by the delay in presentation after the onset of ocular complaints in developing poor countries where health care could be unachievable because of the high cost or of far distance to travel.”

Late diagnoses lead to a higher number of enucleations and more metastatic melanoma:

“A significant number of Arabic patients, unfortunately, present to ocular oncology clinics at a time where the tumor reaches a large size or is associated with complications that make it non-amenable for brachytherapy and end up with enucleation. Therefore, awareness must be increased and early detection improved with prompt referral by the general ophthalmologist to save more eyes and to enhance survival of affected patients.”

Remember, to effectively diagnose Choroidal Melanoma, ophthalmologists just need to remember “MOST.”

The paper could serve as a springboard for more aggressive efforts to raise awareness of uveal melanoma and its symptoms. This could lead to early diagnoses and a higher cure rate without the loss of an eye.

The goal of the ECF Fellowship Program is to help train candidates from underserved countries so they can return and establish programs for the local populace. The fellowship provides training, a stipend, and travel expenses. In return, doctors agree to return to their home country and treat eye cancer patients.

Drs. Ahmad Shokri Zewar and Yacoub A.Yousef’s work demonstrates the value of investing in doctors in underserved areas and attest to the success of the Eye Cancer Foundation fellowships.


Patient Stories

"Very well treated by Dr. Finger. He explained everything I needed to know about my issue with detail and attention, putting me at ease and giving me confidence to handle this problem for the rest of my life.”
N.N.

Read More

REQUEST AN APPOINTMENT

  • This field is for validation purposes and should be left unchanged.

CONNECT AND SHARE